yesterday announced a license
agreement which will see
Munidpharma assume all
for anti-emetic products Aloxi
(palonosetron hydrochloride) and
in the Australian & NZ markets.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 09 Mar 16 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Mar 16
SIGMA Healthcare ceo Mark Hooper yesterday confirmed the company was “starting to see a return to growth in our brand member pipeline,” but said general trading conditions have continued to be challenging in the last quarter.